The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).
 
Evan Y. Yu
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Bayer; Bristol Myers Squibb; Janssen; Loxo/Lilly; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Merck Sharp & Dohme LLC (Inst)
 
Jeffrey C. Goh
Stock and Other Ownership Interests - ICON Cancer Care; Immutep
Honoraria - AstraZeneca; MSD Oncology
Consulting or Advisory Role - BMS; GlaxoSmithKline; Janssen Oncology; MSD
Speakers' Bureau - AstraZeneca/MedImmune; Eisai; Ipsen; Janssen; MSD Oncology; Pfizer/EMD Serono
Travel, Accommodations, Expenses - Bayer; Pfizer/EMD Serono
 
Sang Joon Shin
No Relationships to Disclose
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology (Inst); Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/Merck (Inst); Bristol Myers Squibb Foundation (Inst); Janssen-Cilag (Inst)
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Peter C.C. Fong
Consulting or Advisory Role - MSD
 
Richard Greil
Stock and Other Ownership Interests - Lilly (Inst); Novo Nordisk (Inst)
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie; Abbvie; Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Juan Pablo Sade
No Relationships to Disclose
 
Yi-Hsiu Huang
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen; MSD; Ono Pharmaceutical; Pfizer; Viatris
Consulting or Advisory Role - Astellas Pharma; MSD
 
Gero Kramer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; ferring; janssen; MSD Life Science Foundation; novartis; Sandoz-Novartis
Travel, Accommodations, Expenses - bayer; bayer; Janssen
 
Hiroyoshi Suzuki
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Janssen Oncology; Janssen Research & Development; Lilly; MSD K.K; Nihon Medi-Physics; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Daiichi-Sankyo; Janssen; Kissei Pharmaceutical; Nippon Shinyaku; Novartis; Sanofi; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); Nihonkayaku (Inst)
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Ping Qiu
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
E.J. Dettman
Employment - Merck
Stock and Other Ownership Interests - Merck
Patents, Royalties, Other Intellectual Property - Patent applications
 
April Wang
Employment - Merck
 
Cai Chen
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Razvan Cristescu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Matthew J. Marton
Employment - Merck
Stock and Other Ownership Interests - BodiGuide; Fulgent Genetics; Merck; Teladoc
Patents, Royalties, Other Intellectual Property - Patents issued and pending (Inst)
(OPTIONAL) Uncompensated Relationships - Frontiers Research Foundation
 
Emmanuel S. Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen